Amanda Blalock, NP
Psychiatric/Mental Health · Tyler, TXNPI 1740681279
Payments from drug & device makers
Across 421 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$971
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$948
- Johnson & Johnson$891
- Vanda Pharmaceuticals Inc.$836
- Alkermes, Inc.$697
- plus $3K from 10 others
What the payments were for
- Food & beverage$8,11198%
- Education$1472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 62 | $1,197 |
| Teva Pharmaceuticals USA, Inc. | 43 | $971 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 43 | $948 |
| Johnson & Johnson | 34 | $891 |
| Vanda Pharmaceuticals Inc. | 33 | $836 |
| Alkermes, Inc. | 40 | $697 |
| AbbVie | 44 | $662 |
| Otsuka America Pharmaceutical, Inc. | 38 | $553 |
| Lundbeck LLC | 29 | $471 |
| Indivior Inc. | 17 | $364 |
| Sunovion Pharmaceuticals Inc. | 18 | $281 |
| Axsome Therapeutics, Inc. | 12 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| E.r. Squibb & Sons, L.L.C. | 2 | $46 |
| Corium, LLC | 1 | $30 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA TRINZA$126
- INVEGA SUSTENNA$121
- CAPLYTA$120
- UZEDY$105
How this compares
$8,258 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 118 | $382,178 |
| IngrezzaValbenazine Tosylate | 15 | $129,671 |
| Abilify MaintenaAripiprazole | 42 | $117,442 |
| RexultiBrexpiprazole | 47 | $78,498 |
| AristadaAripiprazole Lauroxil | 22 | $67,501 |
| CaplytaLumateperone Tosylate | 36 | $60,856 |
| UzedyRisperidone | 12 | $42,592 |
| TrintellixVortioxetine Hydrobromide | 56 | $38,070 |
| PerserisRisperidone | 12 | $32,178 |
| Risperdal ConstaRisperidone Microspheres | 14 | $27,320 |
| AuvelityDextromethorphan Hbr/Bupropion | 21 | $22,391 |
| VraylarCariprazine Hcl | 13 | $18,276 |
| Divalproex Sodium ErDivalproex Sodium | 103 | $4,769 |
| Clozapine | 53 | $3,856 |
| Duloxetine Hcl | 101 | $3,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $891 | $409,498132 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $553 | $195,94089 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,197 | $129,67115 claims |
| Alkermes, Inc.Aristada | $697 | $67,50122 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $948 | $60,85636 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $971 | $42,59212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $78 | $38,07056 claims |
| Indivior Inc.Perseris | $364 | $32,17812 claims |
| Axsome Therapeutics, Inc.Auvelity | $216 | $22,39121 claims |
| AbbVieVraylar | $662 | $18,27613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Tyler
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.